Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

Table 2 Number of prescribers for each drug and number of prescribers that received payments

S.No.	Drug Name	Number of prescribers of the drug^a N	Prescribers that received any payments^b N (%)
1.	Lovastatin ER	81	47 (58.02%)
	Rosuvastatin	125,058	60,192 (48.13%)
	Lovastatin	96,189	42,631 (44.32%)
2	Almotriptan	87	53 (60.92%)
	Rizatriptan	224	115 (51.34%)
	Sumatriptan	30,940	15,012 (48.53%)
3	Amlodipine+olmesartan	11,018	6687 (60.69%)
	Telmisartan	2152	1273 (59.15%)
	Irbesartan	35,546	18,308 (51.51%)
4	Ibuprofen+famotidine	116	66 (56.90%)
	Celecoxib	75,422	39,328 (52.14%)
	Ibuprofen	104,759	41,530 (39.64%)
5	Saxagliptin+metformin	5265	3122 (59.30%)
	Sitagliptin	82,593	40,227 (48.71%)
	Metformin	168,819	68,718 (40.70%)
6	Naproxen+esomeprazole	787	498 (63.28%)
	Celecoxib	75,422	39,328 (52.14%)
	Naproxen	79,189	35,057 (44.27%)

^aThe number of prescribers in each trio are not mutually exclusive, i.e. same prescriber could prescribe either 1, 2 or all 3 drugs in the trio
^bThe number (and percent) of prescribers that received any payment from industry is among the prescribers of the specific drug

ISSN: 1472-6963